摘要
目的 探讨奥氮平联合辛伐他汀治疗对患者的临床效果及脂质代谢的影响。方法 选取2012年1月~2015年6月在本院精神科治疗的48例精神分裂症患者采用抽签法进行随机分组,其中观察组(奥氮平+辛伐他汀)和对照组(奥氮平)各24例,疗程8周。结果 治疗前、治疗2周、4周、8周,两组患者的PANSS评分差异无统计学意义(P〉0.05),治疗2周、4周、8周,两组患者的PANSS评分均呈逐渐降低的趋势(P〈0.05);治疗前,两组患者的TG、TC、HDL-C、LDL-C、FPG、Fins、BMI差异无统计学意义(P〉0.05),治疗8周后,观察组患者的TG、TC、LDL-C、FPG、Fins均显著低于对照组(P〈0.05);治疗后,对照组患者的TG、TC、LDL-C、FPG、Fins较治疗前显著提高(P〈0.05)。结论 奥氮平联合辛伐他汀治疗精神分裂症患者不会影响治疗效果,同时能够有效减轻奥氮平治疗过程中引起的血脂、血糖代谢紊乱。
Objective To investigate the effect of olanzapine combined with simvastatin on lipid metabolism in the patients with schizophrenia. Methods 48 patients with schizophrenia were randomly divided into two group, in- eluding observation group (olanzapine + simvastatin) and control group (olanzapine) . The course of treatment for every patients was 8 weeks. Results PANSS scores of patients in the two groups was not statistically significant difference before treatment and after two weeks, four weeks and eight weeks of treatment, (P 〉 0.05 ) . PANSS score of patients in both groups showed a decreased trend (P〈0.05); before treatment, TG, TC, HDL-C, LDL-C, FPG, Fins, BMI of patients in two groups was no significant difference (P〉 0.05 ), after treatment, TG, TC, LDL-C, FPG, Fins in the observation group patients were significantly lower than those in the control group (P 〈 0.05 ); After 8 weeks of treat- ment, TG, TC, LDL-C, FPG, Fins of patients in the control group significantly increased than those before treatment ( P〈0.05 ) . Conclusion Olanzapine combined with simvastatin will not affect the treatment effect in patients with schizophrenia, and can effectively reduce the abnormality in lipids, blood glucose metabolism caused by the olanzap- inc.
出处
《国际精神病学杂志》
2016年第6期985-988,共4页
Journal Of International Psychiatry